IL155871A0 - Use of cci-779 as an antineoplastic agent - Google Patents

Use of cci-779 as an antineoplastic agent

Info

Publication number: IL155871A0
Authority: IL; Israel
Prior art keywords: cci; antineoplastic agent; antineoplastic; agent
Prior art date: 2000-11-15

Application number

IL15587101A

Other languages

English (en)

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-15

Filing date

2001-11-13

Publication date

2003-12-23

2001-11-13 Application filed by Wyeth Corp filed Critical Wyeth Corp

2003-12-23 Publication of IL155871A0 publication Critical patent/IL155871A0/xx

Links

CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title 1
229940034982 antineoplastic agent Drugs 0.000 title 1
239000002246 antineoplastic agent Substances 0.000 title 1
229960000235 temsirolimus Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL15587101A 2000-11-15 2001-11-13 Use of cci-779 as an antineoplastic agent IL155871A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24907700P	2000-11-15	2000-11-15
PCT/US2001/047324 WO2002040000A2 (fr)	2000-11-15	2001-11-13	Utilisation du cci-779 en tant qu'agent antineoplasique

Publications (1)

Publication Number	Publication Date
IL155871A0 true IL155871A0 (en)	2003-12-23

Family

ID=22941961

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL15587101A IL155871A0 (en)	2000-11-15	2001-11-13	Use of cci-779 as an antineoplastic agent
IL155871A IL155871A (en)	2000-11-15	2003-05-12	Use of 779-CCI for the preparation of a drug for the treatment of lupus

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL155871A IL155871A (en)	2000-11-15	2003-05-12	Use of 779-CCI for the preparation of a drug for the treatment of lupus

Country Status (27)

Country	Link
US (3)	US20020091137A1 (fr)
EP (1)	EP1335725B1 (fr)
JP (4)	JP4472251B2 (fr)
KR (1)	KR100827942B1 (fr)
CN (2)	CN1678312A (fr)
AR (1)	AR031341A1 (fr)
AT (1)	ATE393629T1 (fr)
AU (2)	AU2731302A (fr)
BR (1)	BR0115323A (fr)
CA (1)	CA2429020C (fr)
CY (1)	CY1108109T1 (fr)
DE (1)	DE60133831T2 (fr)
DK (1)	DK1335725T3 (fr)
EA (1)	EA007096B1 (fr)
ES (1)	ES2305134T3 (fr)
HU (1)	HUP0400521A3 (fr)
IL (2)	IL155871A0 (fr)
MX (1)	MXPA03004192A (fr)
NO (1)	NO20032181L (fr)
NZ (1)	NZ539668A (fr)
PL (1)	PL207061B1 (fr)
PT (1)	PT1335725E (fr)
SG (1)	SG148031A1 (fr)
SI (1)	SI1335725T1 (fr)
TW (1)	TWI286074B (fr)
WO (1)	WO2002040000A2 (fr)
ZA (1)	ZA200304603B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5362718A (en)	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
TWI286074B (en) *	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
CN104083365A (zh)	2001-02-19	2014-10-08	诺华股份有限公司	癌症的治疗
TWI296196B (en) *	2001-04-06	2008-05-01	Wyeth Corp	Antineoplastic combinations
ZA200603888B (en) *	2001-06-01	2007-05-30	Wyeth Corp	Antineoplastic combinations
CA2447732A1 (fr) *	2001-06-01	2002-12-12	Wyeth	Combinaisons antineoplasiques
JP4547911B2 (ja) *	2002-02-01	2010-09-22	アリアド・ファーマシューティカルズ・インコーポレイテッド	リン含有化合物およびその用途
EP1516597A4 (fr) *	2002-06-27	2010-11-10	Microport Medical Shanghai Co	Stent eluant des medicaments
TWI307277B (en)	2002-07-30	2009-03-11	Wyeth Corp	Parenteral formulations
MXPA05002828A (es) *	2002-09-17	2005-05-27	Wyeth Corp	Formulaciones orales.
JP2006514554A (ja)	2002-11-21	2006-05-11	ワイス	腎細胞癌および他の固形腫瘍の診断法
US20050287532A9 (en) *	2003-02-11	2005-12-29	Burczynski Michael E	Methods for monitoring drug activities in vivo
US7643943B2 (en)	2003-02-11	2010-01-05	Wyeth Llc	Methods for monitoring drug activities in vivo
CA2515677A1 (fr) *	2003-02-11	2004-08-26	Wyeth	Procedes pour controler in vivo des activites de medicaments
UA83484C2 (uk) *	2003-03-05	2008-07-25	Уайт	Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
KR20060006058A (ko) *	2003-04-22	2006-01-18	와이어쓰	항신생물성 배합물
EP1618218A2 (fr) *	2003-04-29	2006-01-25	Wyeth	Procedes de pronostic et de traitement de tumeurs solides
CA2532251A1 (fr) *	2003-07-25	2005-02-10	Wyeth	Formulations de cci-779 lyophilise
AR046194A1 (es) *	2003-11-04	2005-11-30	Mayo Foundation	Metodo de tratamiento del linfoma de celulas del manto
EP1701698B1 (fr) *	2004-01-08	2008-01-16	Wyeth a Corporation of the State of Delaware	Composition pharmaceutique directement compressible pour l'administration orale de cci-779
AR047988A1 (es) *	2004-03-11	2006-03-15	Wyeth Corp	Combinaciones antineoplásicas de cci-779 y rituximab
ZA200706804B (en)	2005-02-03	2008-10-29	Gen Hospital Corp	Method for treating gefitinib resistant cancer
CA2596392A1 (fr) *	2005-02-15	2006-08-24	Wyeth	Formulations orales de cci-779 biodisponibles
WO2007056118A1 (fr)	2005-11-04	2007-05-18	Wyeth	Combinaisons antineoplasiques a base d'inhibiteur de mtop, d'herceptine et/ou de khi-272
PT2275103E (pt) *	2005-11-21	2014-07-24	Novartis Ag	Inibidores de mtor para o tratamento de tumores endócrinos
WO2007075621A1 (fr) *	2005-12-20	2007-07-05	Wyeth	Maitrise de la stabilite de la forme pharmaceutique de cci-779 par l'elimination optimale des impuretes de la substance medicamenteuse
DE102006011507A1 (de) *	2006-03-14	2007-09-20	Lts Lohmann Therapie-Systeme Ag	Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
TW200901989A (en)	2007-04-10	2009-01-16	Wyeth Corp	Anti-tumor activity of CCI-779 in papillary renal cell cancer
US20090076060A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched temsirolimus
EP3142297B1 (fr) *	2007-10-03	2019-02-06	Genesis Technical Systems, Corp.	Anneaux dynamiques asymétriques
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
AU2013205002B2 (en) *	2008-03-21	2016-09-15	The University Of Chicago	Treatment with opioid antagonists and mTOR inhibitors
CA2719134C (fr)	2008-03-21	2015-06-30	The University Of Chicago	Traitement avec des antagonistes des opioides et des inhibiteurs mtor
EP2915532B1 (fr)	2008-06-17	2016-10-19	Wyeth LLC	Combinaisons antinéoplasiques contenant du HKI-272 et de la vinorelbine
CN115990181A (zh)	2008-08-04	2023-04-21	惠氏有限责任公司	4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
CA2755789C (fr)	2009-04-06	2016-01-19	Wyeth Llc	Regime de traitement a l'aide de neratinib pour un cancer du sein
WO2010132233A1 (fr) *	2009-05-13	2010-11-18	The Trustees Of The University Of Pennsylvania	Thérapie antinéoplasique combinée
WO2011151704A2 (fr) *	2010-06-02	2011-12-08	Fresenius Kabi Oncology Ltd.	Compositions pharmaceutiques stables d'esters de rapamycine
US9745941B2 (en) *	2014-04-29	2017-08-29	Ford Global Technologies, Llc	Tunable starter resistor
JP6533866B2 (ja) *	2015-08-24	2019-06-19	山西亜宝保健品有限公司ＳｈａｎｘｉＹａｂａｏＨｅａｌｔｈＰｒｏｄｕｃｔｓＣｏ．，Ｌｔｄ．	抗腫瘍薬を製造するための、ジヒドロキシアセトンの用途
CN111110676A (zh) *	2020-03-07	2020-05-08	天津医科大学总医院	阿帕替尼及联合cci-779在制备肺癌药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US3993749A (en)	1974-04-12	1976-11-23	Ayerst Mckenna And Harrison Ltd.	Rapamycin and process of preparation
US4885171A (en)	1978-11-03	1989-12-05	American Home Products Corporation	Use of rapamycin in treatment of certain tumors
US5206018A (en)	1978-11-03	1993-04-27	Ayerst, Mckenna & Harrison, Inc.	Use of rapamycin in treatment of tumors
BE877700A (fr) *	1978-11-03	1980-01-14	Ayerst Mckenna & Harrison	Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4401653A (en)	1981-03-09	1983-08-30	Ayerst, Mckenna & Harrison Inc.	Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en)	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5080899A (en)	1991-02-22	1992-01-14	American Home Products Corporation	Method of treating pulmonary inflammation
US5078999A (en)	1991-02-22	1992-01-07	American Home Products Corporation	Method of treating systemic lupus erythematosus
US5321009A (en)	1991-04-03	1994-06-14	American Home Products Corporation	Method of treating diabetes
ATE135583T1 (de)	1991-06-18	1996-04-15	American Home Prod	Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen
ZA924953B (en)	1991-07-25	1993-04-28	Univ Louisville Res Found	Method of treating ocular inflammation
US5286731A (en)	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory bowel disease
US5286730A (en)	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory disease
US5516781A (en)	1992-01-09	1996-05-14	American Home Products Corporation	Method of treating restenosis with rapamycin
US5288711A (en)	1992-04-28	1994-02-22	American Home Products Corporation	Method of treating hyperproliferative vascular disease
ZA935112B (en)	1992-07-17	1994-02-08	Smithkline Beecham Corp	Rapamycin derivatives
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5561138A (en)	1994-12-13	1996-10-01	American Home Products Corporation	Method of treating anemia
US5496832A (en)	1995-03-09	1996-03-05	American Home Products Corporation	Method of treating cardiac inflammatory disease
PT1318837E (pt)	2000-08-11	2004-12-31	Wyeth Corp	Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
TWI286074B (en) *	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en)	2001-04-06	2008-05-01	Wyeth Corp	Antineoplastic combinations
TWI233359B (en)	2001-04-06	2005-06-01	Wyeth Corp	Pharmaceutical composition for treating neoplasm
UA77200C2 (en)	2001-08-07	2006-11-15	Wyeth Corp	Antineoplastic combination of cci-779 and bkb-569

2001
- 2001-11-05 TW TW090127415A patent/TWI286074B/zh not_active IP Right Cessation
- 2001-11-13 MX MXPA03004192A patent/MXPA03004192A/es active IP Right Grant
- 2001-11-13 DE DE60133831T patent/DE60133831T2/de not_active Expired - Lifetime
- 2001-11-13 KR KR1020037006542A patent/KR100827942B1/ko not_active Expired - Lifetime
- 2001-11-13 WO PCT/US2001/047324 patent/WO2002040000A2/fr not_active Ceased
- 2001-11-13 HU HU0400521A patent/HUP0400521A3/hu unknown
- 2001-11-13 CA CA002429020A patent/CA2429020C/fr not_active Expired - Lifetime
- 2001-11-13 JP JP2002542375A patent/JP4472251B2/ja not_active Expired - Lifetime
- 2001-11-13 CN CNA018189261A patent/CN1678312A/zh active Pending
- 2001-11-13 PL PL362740A patent/PL207061B1/pl unknown
- 2001-11-13 DK DK01996175T patent/DK1335725T3/da active
- 2001-11-13 SI SI200130829T patent/SI1335725T1/sl unknown
- 2001-11-13 CN CN2010101653331A patent/CN102058588A/zh active Pending
- 2001-11-13 EP EP01996175A patent/EP1335725B1/fr not_active Expired - Lifetime
- 2001-11-13 AT AT01996175T patent/ATE393629T1/de not_active IP Right Cessation
- 2001-11-13 NZ NZ539668A patent/NZ539668A/en unknown
- 2001-11-13 US US10/010,584 patent/US20020091137A1/en not_active Abandoned
- 2001-11-13 PT PT01996175T patent/PT1335725E/pt unknown
- 2001-11-13 IL IL15587101A patent/IL155871A0/xx unknown
- 2001-11-13 AU AU2731302A patent/AU2731302A/xx active Pending
- 2001-11-13 SG SG200505237-8A patent/SG148031A1/en unknown
- 2001-11-13 BR BR0115323-4A patent/BR0115323A/pt not_active Application Discontinuation
- 2001-11-13 ES ES01996175T patent/ES2305134T3/es not_active Expired - Lifetime
- 2001-11-13 EA EA200300566A patent/EA007096B1/ru not_active IP Right Cessation
- 2001-11-14 AR ARP010105310A patent/AR031341A1/es unknown
2003
- 2003-02-26 US US10/374,644 patent/US7189735B2/en not_active Expired - Lifetime
- 2003-05-12 IL IL155871A patent/IL155871A/en active IP Right Grant
- 2003-05-14 NO NO20032181A patent/NO20032181L/no not_active Application Discontinuation
- 2003-06-12 ZA ZA200304603A patent/ZA200304603B/en unknown
2007
- 2007-02-01 US US11/701,109 patent/US7781446B2/en not_active Expired - Fee Related
- 2007-03-27 AU AU2007201324A patent/AU2007201324B2/en not_active Expired
2008
- 2008-06-02 CY CY20081100573T patent/CY1108109T1/el unknown
2009
- 2009-09-18 JP JP2009216883A patent/JP2010018620A/ja active Pending
2014
- 2014-01-15 JP JP2014005231A patent/JP2014088430A/ja not_active Withdrawn
2015
- 2015-12-10 JP JP2015241449A patent/JP2016094444A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
NZ539668A (en)	2007-06-29
HUP0400521A3 (en)	2007-05-29
KR100827942B1 (ko)	2008-05-13
PT1335725E (pt)	2008-06-19
IL155871A (en)	2012-03-29
SG148031A1 (en)	2008-12-31
US20020091137A1 (en)	2002-07-11
CN1678312A (zh)	2005-10-05
EA007096B1 (ru)	2006-06-30
CA2429020A1 (fr)	2002-05-23
US7781446B2 (en)	2010-08-24
SI1335725T1 (sl)	2008-08-31
AU2007201324A1 (en)	2007-04-19
US20070142425A1 (en)	2007-06-21
AU2007201324B2 (en)	2010-11-18
HUP0400521A2 (hu)	2004-06-28
AR031341A1 (es)	2003-09-17
DK1335725T3 (da)	2008-06-30
CY1108109T1 (el)	2014-02-12
DE60133831T2 (de)	2009-05-20
EP1335725A2 (fr)	2003-08-20
HK1058008A1 (en)	2004-04-30
DE60133831D1 (de)	2008-06-12
TWI286074B (en)	2007-09-01
KR20040029309A (ko)	2004-04-06
MXPA03004192A (es)	2003-09-22
CN102058588A (zh)	2011-05-18
PL362740A1 (en)	2004-11-02
JP4472251B2 (ja)	2010-06-02
JP2016094444A (ja)	2016-05-26
US7189735B2 (en)	2007-03-13
NO20032181D0 (no)	2003-05-14
US20030153593A1 (en)	2003-08-14
EA200300566A1 (ru)	2003-10-30
EP1335725B1 (fr)	2008-04-30
WO2002040000A3 (fr)	2002-09-06
ATE393629T1 (de)	2008-05-15
JP2010018620A (ja)	2010-01-28
AU2731302A (en)	2002-05-27
WO2002040000A2 (fr)	2002-05-23
NO20032181L (no)	2003-05-14
CA2429020C (fr)	2009-05-26
JP2014088430A (ja)	2014-05-15
PL207061B1 (pl)	2010-10-29
JP2004517065A (ja)	2004-06-10
ES2305134T3 (es)	2008-11-01
ZA200304603B (en)	2004-09-13
BR0115323A (pt)	2004-02-17

Publication	Publication Date	Title
AU2731302A (en)	2002-05-27	Use of cci-779 as an antineoplastic agent
GB2359254B (en)	2002-06-19	Formulation
SI1337521T1 (sl)	2006-12-31	Soli izotiazol-4-karboksamida in njihova uporaba kot antihiperproliferacijska sredstva
AU8986501A (en)	2002-03-22	Exemestane as chemopreventing agent
GB0000891D0 (en)	2000-03-08	Formulation
EP1151667A3 (fr)	2003-01-29	Agent d'activation de plantes
GB2366727B (en)	2005-01-19	Antithixotropic cosmetic agent
EP1291461A4 (fr)	2004-06-16	Recuperateur de couleur
GB0019412D0 (en)	2000-09-27	New imaging agent
AU2001275696A1 (en)	2002-02-05	Therapeutic agent
AU5864901A (en)	2001-12-11	4-aminoquinolines as antiinfective agents
GB0024517D0 (en)	2000-11-22	Use of medicaments
GB0023220D0 (en)	2000-11-01	Corticosteroid formulation
GB0009127D0 (en)	2000-05-31	Vasodilatory agent
GB9921062D0 (en)	1999-11-10	Use of cholestrol-lowering agent
GB0021927D0 (en)	2000-10-25	Use of pharmaceutical combination
GB0007112D0 (en)	2000-05-17	Formulation
GB0023069D0 (en)	2000-11-01	Formulation
GB0001144D0 (en)	2000-03-08	Glysophosate formulation
GB0004124D0 (en)	2000-04-12	Formulation
GB0010846D0 (en)	2000-06-28	Formulation
PL340617A1 (en)	2001-12-17	Derivatives of 2-acylpyridine
SI1301469T1 (sl)	2006-10-31	Priprava 4-tioalkilbromobenzenskih derivatov
GB0109520D0 (en)	2001-06-06	Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as njk-inhibitors
GB0017049D0 (en)	2000-08-30	Therapeutic agent